The role of hypoxia inducible factor-1alpha in gynecological cancer

Critical Reviews in Oncology/Hematology

Volumn 78, Issue 3, 2011, Pages 173-184

  Seeber, Laura M S ^a   Horrée, Nicole ^a   Vooijs, Marc A G G ^a,b   Heintz, A Peter M ^a   van der Wall, Elsken ^a   Verheijen, René H M ^a   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cervical cancer; Endometrial cancer; Hypoxia; Hypoxia inducible factor 1alpha; Ovarian cancer; Prognosis; Therapy

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

CANCER THERAPY; CARCINOGENESIS; DNA POLYMORPHISM; DRUG TARGETING; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; PROGNOSIS; PROTEIN FUNCTION; REVIEW; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER;

ANOXIA; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT;

EID: 79955658283     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.05.003     Document Type: Review

References (129)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000, 35:71-103.
3. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(Suppl. 5):10-17.
4. Bos R., van der Groep P., Greijer A.E., et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581.
5. Vleugel M.M., Greijer A.E., Shvarts A., et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 2005, 58:172-177.
6. Matsuyama T., Nakanishi K., Hayashi T., et al. Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci 2005, 96:176-182.
7. Nakanishi K., Hiroi S., Tominaga S., et al. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 2005, 11:2583-2590.
8. Unruh A., Ressel A., Mohamed H.G., et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22:3213-3220.
9. Kurokawa T., Miyamoto M., Kato K., et al. Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 2003, 89:1042-1047.
10. Le Q.T., Denko N.C., Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004, 23:293-310.
11. Hoeckel M., Schlenger K., Hoeckel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999, 59:4525-4528.
12. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001, 18:243-259.
13. Harrison L., Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004, 9(Suppl. 5):31-40.
14. Greijer A.E., de Jong M.C., Scheffer G.L., Shvarts A., van Diest P.J., van der Wall E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 2005, 27:43-49.
15. Stone H.B., Brown J.M., Phillips T.L., Sutherland R.M. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res 1993, 136:422-434.
16. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., Koukourakis M.I. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002, 95:1055-1063.
17. Huang L.E., Arany Z., Livingston D.M., Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996, 271:32253-32259.
18. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578.
19. Ratcliffe P.J., O'Rourke J.F., Maxwell P.H., Pugh C.W. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998, 201:1153-1162.
20. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000, 88:1474-1480.
21. Greijer A.E., van der Groep P., Kemming D., et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005, 206:291-304.
22. Vaughan-Jones R.D., Spitzer K.W. Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol 2002, 80:579-596.
23. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994, 219:713-725.
24. Thomas K.A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996, 271:603-606.
25. Schmid T., Zhou J., Brune B. HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med 2004, 8:423-431.
26. Koshiji M., Huang L.E. Dynamic balancing of the dual nature of HIF-1alpha for cell survival. Cell Cycle 2004, 3:853-854.
27. Furge K.A., Zhang Y.W., Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000, 19:5582-5589.
28. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
29. Hara S., Nakashiro K., Klosek S.K., Ishikawa T., Shintani S., Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol 2006, 42:593-598.
30. Eckerich C., Zapf S., Fillbrandt R., Loges S., Westphal M., Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer 2007, 121:276-283.
31. Gort E.H., Groot A.J., van der Wall E., van Diest P.J., Vooijs M.A. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 2008, 8:60-67.
32. Kulshreshtha R., Davuluri R.V., Calin G.A., Ivan M. A microRNA component of the hypoxic response. Cell Death Differ 2008, 15:667-671.
33. Kulshreshtha R., Ferracin M., Negrini M., Calin G.A., Davuluri R.V., Ivan M. Regulation of microRNA expression: the hypoxic component. Cell Cycle 2007, 6:1426-1431.
34. Kulshreshtha R., Ferracin M., Wojcik S.E., et al. A microRNA signature of hypoxia. Mol Cell Biol 2007, 27:1859-1867.
35. Camps C., Buffa F.M., Colella S., et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008, 14:1340-1348.
36. Ivan M., Harris A.L., Martelli F., Kulshreshtha R. Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med 2008, 12:1426-1431.
37. Giannakakis A., Sandaltzopoulos R., Greshock J., et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008, 7:255-264.
38. Kaelin W.G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007, 13:680s-684s.
39. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001, 21:3995-4004.
40. Zundel W., Schindler C., Haas-Kogan D., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000, 14:391-396.
41. Gort E.H., Groot A.J., Derks van de Ven T.L., et al. Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene 2006, 25:6123-6127.
42. Li Y.M., Zhou B.P., Deng J., Pan Y., Hay N., Hung M.C. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 2005, 65:3257-3263.
43. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001, 12:363-369.
44. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002, 277:38205-38211.
45. Ravi R., Mookerjee B., Bhujwalla Z.M., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000, 14:34-44.
46. Vleugel M.M., Greijer A.E., van der Wall E., van Diest P.J. Mutation analysis of the HIF-1alpha oxygen-dependent degradation domain in invasive breast cancer. Cancer Genet Cytogenet 2005, 163:168-172.
47. Vleugel M.M., Bos R., Buerger H., et al. No amplifications of hypoxia-inducible factor-1alpha gene in invasive breast cancer: a tissue microarray study. Cell Oncol 2004, 26:347-351.
48. Fu X.S., Choi E., Bubley G.J., Balk S.P. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005, 63:215-221.
49. Horrée N., Groot A.J., van Hattem W., Heintz A.P., Vooijs M.A., van Diest P.J. HIF-1alpha gene mutations are associated with higher microvessel density in endometrial carcinomas. Histopathology 2008, 52:637-639.
50. 2 tension measurements. Cancer Res 1991, 51:6098-6102.
51. Haugland H.K., Vukovic V., Pintilie M., et al. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 2002, 53:854-861.
52. Hutchison G.J., Valentine H.R., Loncaster J.A., et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004, 10:8405-8412.
53. Mayer A., Wree A., Hoeckel M., Leo C., Pilch H., Vaupel P. Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 2004, 64:5876-5881.
54. Jankovic B., Aquino-Parsons C., Raleigh J.A., et al. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom 2006, 70:45-55.
55. Dellas K., Bache M., Pigorsch S.U., et al. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 2008, 184:169-174.
56. Hedley D., Pintilie M., Woo J., et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 2003, 9:5666-5674.
57. Mayer A., Hoeckel M., Wree A., Vaupel P. Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res 2005, 11:2768-2773.
58. Loncaster J.A., Harris A.L., Davidson S.E., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001, 61:6394-6399.
59. Airley R., Loncaster J., Davidson S., et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001, 7:928-934.
60. Nordsmark M., Loncaster J., Aquino-Parsons C., et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 2003, 67:35-44.
61. Horrée N., van Diest P.J., van der Groep P., Sie-Go D.M., Heintz A.P. Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 2007, 29:219-227.
62. Speroff L., Glass R.H., Kase N.G. Clinical gynecologic endocrinology and infertility 1994, Williams and Wilkins, Sydney.
63. Critchley H.O., Osei J., Henderson T.A., et al. Hypoxia-inducible factor-1alpha expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2 (EP2). Endocrinology 2006, 147:744-753.
64. Zhang J., Salamonsen L.A. Expression of hypoxia-inducible factors in human endometrium and suppression of matrix metalloproteinases under hypoxic conditions do not support a major role for hypoxia in regulating tissue breakdown at menstruation. Hum Reprod 2002, 17:265-274.
65. Acs G., Xu X., Chu C., Acs P., Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004, 100:2376-2386.
66. Ozbudak I.H., Karaveli S., Simsek T., Erdogan G., Pestereli E. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol 2008, 108:603-608.
67. Pansare V., Munkarah A.R., Schimp V., et al. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol 2007, 20:35-43.
68. Schimp V.L., li-Fehmi R., Solomon L.A., et al. The racial disparity in outcomes in endometrial cancer: could this be explained on a molecular level?. Gynecol Oncol 2006, 102:440-446.
69. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.
70. Risinger J.I., Hayes A.K., Berchuck A., Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997, 57:4736-4738.
71. Kong D., Suzuki A., Zou T.T., et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997, 17:143-144.
72. Cohn D.E., Basil J.B., Venegoni A.R., et al. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol 2000, 79:101-106.
73. Pijnenborg J.M., Wijnakker M., Hagelstein J., Delvoux B., Groothuis P.G. Hypoxia contributes to development of recurrent endometrial carcinoma. Int J Gynecol Cancer 2007, 17:897-904.
74. Miyazawa M., Yasuda M., Fujita M., et al. Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch Gynecol Obstet 2009, 279:789-796.
75. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000, 60:4693-4696.
76. Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995, 55:4420-4424.
77. Tang X., Zhang Q., Nishitani J., Brown J., Shi S., Le A.D. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res 2007, 13:2568-2576.
78. Lechner M.S., Laimins L.A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994, 68:4262-4273.
79. Bachtiary B., Schindl M., Potter R., et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003, 9:2234-2240.
80. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998, 392:405-408.
81. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
82. Hoeckel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56:4509-4515.
83. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002, 20:680-687.
84. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999, 53:99-104.
85. Rofstad E.K., Sundfor K., Lyng H., Trope C.G. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000, 83:354-359.
86. Burri P., Djonov V., Aebersold D.M., et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:494-501.
87. Ishikawa H., Sakurai H., Hasegawa M., et al. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004, 60:513-521.
88. Kirkpatrick J.P., Rabbani Z.N., Bentley R.C., et al. Elevated CAIX expression is associated with an increased risk of distant failure in early-stage cervical cancer. Biomark Insights 2008, 3:45-55.
89. Osada R., Horiuchi A., Kikuchi N., et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007, 38:1310-1320.
90. Lee S., Garner E.I., Welch W.R., Berkowitz R.S., Mok S.C. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 2007, 106:311-317.
91. Wong C., Wellman T.L., Lounsbury K.M. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003, 91:513-517.
92. Iida T., Yasuda M., Miyazawa M., et al. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression. Arch Gynecol Obstet 2008, 277:539-546.
93. Birner P., Schindl M., Obermair A., Breitenecker G., Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001, 7:1661-1668.
94. Shimogai R., Kigawa J., Itamochi H., et al. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 2008, 18:499-505.
95. Nakayama K., Kanzaki A., Hata K., et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 2002, 176:215-223.
96. Wenger R.H., Kvietikova I., Rolfs A., Gassmann M., Marti H.H. Hypoxia-inducible factor-1 alpha is regulated at the post-mRNA level. Kidney Int 1997, 51:560-563.
97. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996, 23:40-47.
98. Vasey P.A., Atkinson R., Coleman R., et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001, 84:170-178.
99. Nakai H., Watanabe Y., Ueda H., Hoshiai H. Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer Lett 2007, 251:164-167.
100. Cantuaria G., Fagotti A., Ferrandina G., et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001, 92:1144-1150.
101. Hoeckel M., Schlenger K., Hoeckel S., Aral B., Schaffer U., Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998, 79:365-369.
102. Vaupel P., Mayer A., Hoeckel M. Oxygenation status of primary and recurrent squamous cell carcinomas of the vulva. Eur J Gynaecol Oncol 2006, 27:142-146.
103. Stone J.E., Parker R., Gilks C.B., Stanbridge E.J., Liao S.Y., Aquino-Parsons C. Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis. Eur J Gynaecol Oncol 2005, 26:31-35.
104. Orr-Urtreger A., Bar-Shira A., Matzkin H., Mabjeesh N.J. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate 2007, 67:8-13.
105. Chau C.H., Permenter M.G., Steinberg S.M., et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005, 4:1222-1225.
106. Kuwai T., Kitadai Y., Tanaka S., et al. Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. Oncol Rep 2004, 12:1033-1037.
107. Fransen K., Fenech M., Fredrikson M., Dabrosin C., Soderkvist P. Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. Mol Carcinog 2006, 45:833-840.
108. Tanimoto K., Yoshiga K., Eguchi H., et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003, 24:1779-1783.
109. Ling T.S., Shi R.H., Zhang G.X., Zhu H., Yu L.Z., Ding X.F. Common single nucleotide polymorphism of hypoxia-inducible factor-1alpha and its impact on the clinicopathological features of esophageal squamous cell carcinoma. Chin J Dig Dis 2005, 6:155-158.
110. Konac E., Onen H.I., Metindir J., Alp E., Biri A.A., Ekmekci A. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev 2007, 31:102-109.
111. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
112. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003, 2:803-811.
113. Rapisarda A., Shoemaker R.H., Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004, 3:172-175.
114. Rapisarda A., Melillo G. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway. Oncogene 2007, 26:6875-6884.
115. Ackermann S., Beckmann M.W., Thiel F., Bogenrieder T. Topotecan in cervical cancer. Int J Gynecol Cancer 2007, 17:1215-1223.
116. Armstrong D.K., Bookman M.A., McGuire W., Bristow R.E., Schilder J.M. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2007, 105:667-671.
117. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004, 3:233-244.
118. O'Donnell J.L., Joyce M.R., Shannon A.M., Harmey J., Geraghty J., Bouchier-Hayes D. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat Rev 2006, 32:407-416.
119. Minet E., Mottet D., Michel G., et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 1999, 460:251-256.
120. Jiang H., Feng Y. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. Int J Gynecol Cancer 2006, 16(Suppl. 1):405-412.
121. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19:535-542.
122. Duyndam M.C., van Berkel M.P., Dorsman J.C., Rockx D.A., Pinedo H.M., Boven E. Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007, 74:191-201.
123. Rapisarda A., Uranchimeg B., Scudiero D.A., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002, 62:4316-4324.
124. Mabjeesh N.J., Post D.E., Willard M.T., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002, 62:2478-2482.
125. Koh M.Y., Spivak-Kroizman T., Venturini S., et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008, 7:90-100.
126. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
127. Koukourakis M.I., Simopoulos C., Polychronidis A., et al. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?. Anticancer Res 2003, 23:1673-1680.
128. Pore N., Jiang Z., Gupta A., Cerniglia G., Kao G.D., Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006, 66:3197-3204.
129. Seeber LMS, Horrée N, Van der Groep P, Van der Wall E, Verheijen RHM, Van Diest PJ. Necrosis related HIF-1α expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer; in press.